The $1.50 central target is a fallback objective drawn from public market and technical discussion, not an analyst consensus, because AquaBounty Technologies, Inc. (NASDAQ: AQB) has no credible, current sell-side price targets. With the stock near $0.95, reaching $1.50 would require roughly 58% upside, a very large move for a company that has wound down its core aquaculture operations.

The $1.00 central target is the Nasdaq Capital Market's minimum bid price requirement — a regulatory milestone, not an analyst price target. Because Fathom's analyst coverage is too thin to form a meaningful consensus, the target was established from public discussion of the Nasdaq listing rule rather than from analyst estimates.

The central target is $1.00 , representing a roughly 92% move from the latest price near $0.52 — a very large required advance. This target is drawn from public discussion and the Nasdaq $1.00 minimum-bid-price listing threshold, not from a consensus of current analyst price targets.

Fathom Holdings is expected to report its third quarter 2026 results on Wednesday, November 11, 2026, before the market opens, with a conference call scheduled for November 10 at 5:00 PM ET. Consensus estimates point to revenue near $128.19 million, up from roughly $115.3 million in the year-ago period, alongside a narrower per-share loss.

The central target used in this analysis is $2.50 , reflecting the most recent Wall Street price target, from Roth MKM (analyst George Kelly, Buy rating, reiterated May 2026). With the latest verified price near $1.49–$1.53 , reaching $2.50 would require roughly 68% upside — a very large move.

The $4.75 target reflects the only currently published analyst price objective on REED , issued by Alliance Global Partners, not a multi-analyst consensus. Because REED has effectively a single active covering analyst, no meaningful average or consensus price target exists; the $4.75 figure is used as a publicly discussed objective.

The central $11.50 target is the arithmetic mean of four verified analyst price targets: Maxim Group ($10), Ladenburg Thalmann ($10), Roth MKM ($11) and Brookline Capital Markets ($15). The four targets span a wide $10 to $15 range, reflecting genuine disagreement about the company's clinical and regulatory prospects.

GEN Restaurant Group (GENK) is scheduled to report third-quarter 2026 results — the quarter ended September 30, 2026 — after the market close on November 10, 2026. Wall Street consensus calls for a net loss of $0.06 per share , wider than the $0.02 per-share loss reported in the year-ago quarter.

Reed's, Inc. (REED) is scheduled to report results for the third quarter of 2026 — the three months ended September 30, 2026 — on November 11, 2026. Consensus estimates from a single covering analyst point to a net loss of roughly $0.26 per share, narrower than the $0.48 per-share loss reported a year earlier.

Cellectar Biosciences reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share , matching the consensus estimate of a $0.46 loss. The net loss widened from $4.4 million, or $1.41 per share , in the same quarter a year earlier, largely on higher clinical-trial spending.

The central $3.00 target used here is not a multi-analyst consensus. It reflects the most recent public price target from a single firm, Maxim Group's Allen Klee, set in August 2026, after being lowered from $5.00. With shares recently trading near $0.98, reaching $3.00 would require a gain of roughly 200% — a very large move for any stock, let alone a thinly covered micro-cap.

Dolphin Entertainment (DLPN) is expected to report Q3 2026 results on or around November 11, 2026 , after the market close. Wall Street consensus points to a loss of $0.04 per share on revenue of approximately $15.2 million .

The $5.00 target used here is a technical and valuation objective drawn from public market discussion, not an analyst consensus, because UONEK lacks credible, current analyst price targets. With Class D shares recently trading near $3.50, reaching $5.00 implies roughly 43% upside — a substantial move, though still well below the split-adjusted 52-week high of $10.90.

Bionano Genomics (NASDAQ: BNGO) is scheduled to report third quarter 2026 results after the market close on November 10, 2026, with a conference call at 4:30 p.m. ET. Consensus revenue estimates stand at approximately $8.44 million, while the company previously guided Q3 2026 revenue to a range of $8.2 million to $8.6 million, up 11% to 16% year over year.

The central $5 target is the arithmetic mean of two verified analyst price targets: $4 from Maxim Group and $6 from H.C. Wainwright. With the stock near $1.16, reaching $5 would require a roughly 330% advance—a very large move by any standard.

ACCESS Newswire reported third quarter 2026 earnings per share (EPS) of $0.14 , beating the consensus estimate of $0.11 . Total revenue came in at $5.52 million , slightly below analyst expectations of roughly $5.7 million .

The central target discussed here is $6 , a reference point drawn from scattered public discussion of Urban One's stock price rather than a formal analyst consensus. At a recent price near $3.95 , reaching $6 would require a rise of roughly 50% or more — a very large move for a small-cap media name.

The $5.00 central target is the arithmetic mean of two verified analyst price targets currently in place for Intrusion Inc. (INTZ) , a Plano, Texas-based cybersecurity company. The two targets are unusually far apart: $1.00 from H.C. Wainwright and $9.00 from Ascendiant Capital Markets, reflecting deep disagreement about the company's outlook.

The central price target of $12.50 is the arithmetic mean of two verified analyst price targets — $12 and $13 — both carrying Buy ratings. At a recent price near $3.37, reaching $12.50 would require roughly 271% upside , a very large move by any standard.

Intrusion Inc. (INTZ) is scheduled to report its third-quarter 2026 results, covering the period ended September 30, 2026, with the announcement expected around November 12, 2026. Wall Street consensus points to a net loss of roughly $0.07 per share on revenue of approximately $2.1 million, which would mark a meaningful sequential rebound from Q2 2026.